View Older Stories View More Recent Stories

Dec 20, 2017 08:00AM AbbVie's Upadacitinib Shows Positive Results as Monotherapy in Phase 3 Rheumatoid Arthritis Study, Meeting All Primary and Key Secondary Endpoints
Dec 19, 2017 08:00AM AbbVie to Present at the Goldman Sachs 10th Annual Healthcare CEOs Unscripted: A View from the Top
Dec 12, 2017 07:31AM AbbVie (ABBV) Phase 3 Study of VENCLEXTA/ VENCLYXTO in Combination with Rituxan Meets Primary Endpoint
Dec 12, 2017 07:30AM AbbVie Announces Phase 3 Study of VENCLEXTA™/ VENCLYXTO™ (venetoclax) in Combination with Rituxan® (rituximab) Meets its Primary Endpoint
Dec 11, 2017 10:00AM IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host Disease -- A Serious, Possibly Life-Threatening Condition
Dec 11, 2017 06:19AM Janssen Research & Development (JNJ) Reports Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5-Yr Follow-Up Data of IMBRUVICA (ibrutinib)
Dec 11, 2017 06:15AM AbbVie (ABBV) Announces Updated 3-Yr Follow-Up Data on RESONATE-2 study (PCYC-1115/1116); IMBRUVICA (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes
Dec 9, 2017 12:03PM IMBRUVICA® (ibrutinib) Pooled Analysis Suggests Benefit in Progression-Free Survival (PFS) at 3.5 Years in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
Dec 9, 2017 09:00AM IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes and Quality of Life Experience in Chronic Lymphocytic Leukemia (CLL) Patients
Dec 5, 2017 08:01AM AbbVie (ABBV) Announces IMBRUVICA Plus Rituximab Phase 3 iNNOVATE Trial in Rare Waldenstrom's Macroglobulinemia Met Primary Endpoint
Dec 5, 2017 08:00AM IMBRUVICA® (ibrutinib) Plus Rituximab Phase 3 iNNOVATE Trial in Rare Waldenström's Macroglobulinemia Met Primary Endpoint
Dec 4, 2017 08:10AM AbbVie (ABBV) Says Risankizumab Met All Primary Endpoints in Fourth Pivotal Phase 3 Psoriasis Study
Dec 4, 2017 08:03AM Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study
Nov 21, 2017 09:27AM AbbVie (ABBV) Says Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at ASH
Nov 21, 2017 09:26AM Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting & Exposition, Highlighting AbbVie's Commitment to Helping Blood Cancer
Nov 15, 2017 07:00AM AbbVie to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
Nov 14, 2017 04:46PM Glenview Capital Enters Comcast (CMCSA), CVS (CVS), Twitter (TWTR) (more...) - 13F
Nov 3, 2017 08:00AM AbbVie to Present at the Jefferies 2017 London Healthcare Conference
Nov 1, 2017 12:00PM AbbVie (ABBV) Announces Positive Phase 3 Extension Study Data for Elagolix for Management of Endometriosis with Associated Pain
Nov 1, 2017 12:00PM AbbVie Announces Positive Phase 3 Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain
Oct 27, 2017 07:40AM AbbVie Reports Third-Quarter 2017 Financial Results
Oct 27, 2017 07:30AM AbbVie Increases Quarterly Dividend by 11 Percent
Oct 27, 2017 07:01AM AbbVie (ABBV) Announces FDA Priority Review for Elagolix for Management of Endometriosis with Associated Pain
Oct 27, 2017 07:00AM AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain
Oct 26, 2017 08:47AM AbbVie (ABBV) Says Risankizumab Met All Co-Primary and Ranked Secondary Endpoints in Three Pivotal Phase 3 Psoriasis Studies
Oct 26, 2017 08:02AM Risankizumab Meets All Co-Primary and Ranked Secondary Endpoints, Achieving Significantly Greater Efficacy Versus Standard Biologic Therapies in Three Pivotal Phase 3 Psoriasis Studies
Oct 25, 2017 07:41AM Dow, S&P gain but Nasdaq dips as healthcare lags
Oct 24, 2017 05:15PM DDF notes major collaboration between portfolio company Alector and AbbVie to advance novel class of immune therapies for patients with Alzheimer's disease
Oct 24, 2017 09:01AM AbbVie (ABBV) to Showcase Immunology Portfolio with New and Late-Breaking Data at ACR/ARHP
Oct 24, 2017 09:00AM AbbVie to Showcase Robust Immunology Portfolio with New and Late-Breaking Data at the 2017 ACR/ARHP Annual Meeting
Oct 24, 2017 07:10AM AbbVie (ABBV) and Alector Announce Pact to Advance Novel Class of Immune Therapies for Patients with AD
Oct 24, 2017 07:00AM Alector and AbbVie Announce Collaboration to Advance a Novel Class of Immune Therapies for Patients with Alzheimer's Disease
Oct 18, 2017 08:35AM AbbVie (ABBV) and Harpoon Therapeutics Enter Immuno-Oncology Research Collaboration
Oct 18, 2017 08:30AM AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration
Oct 18, 2017 08:00AM AbbVie to Present at the 2017 Credit Suisse Health Care Conference
Oct 11, 2017 03:00PM AbbVie (ABBV) Demonstrates Leadership in HCV with New MAVYRET Data to be Presented at AASLD
Oct 11, 2017 02:57PM AbbVie Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017
Oct 10, 2017 08:10AM AbbVie (ABBV), Turnstone Biologics Announce Pact on Viral Immunotherapies in Oncology
Oct 10, 2017 08:00AM AbbVie and Turnstone Biologics Announce Global Collaboration on Viral Immunotherapies in Oncology
Oct 9, 2017 08:00AM AbbVie to Host Third-Quarter 2017 Earnings Conference Call
Sep 28, 2017 08:01AM AbbVie (ABBV) Reports Resolution of HUMIRA Patent Disputes with Amgen (AMGN)
Sep 28, 2017 08:00AM AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Amgen
Sep 27, 2017 05:45AM AbbVie (ABBV) Reports Approval of MAVIRET (glecaprevir/pibrentasvir) in Japan
Sep 27, 2017 12:53AM AbbVie Announces Approval of MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in Japan
Sep 22, 2017 07:01AM AbbVie (ABBV), Bristol-Myers Squibb (BMY) Announce Pact to Evaluate Therapeutic Regimen in Advanced Solid Tumors
Sep 22, 2017 07:00AM AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors
Sep 22, 2017 06:59AM AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors
Sep 18, 2017 11:31AM AbbVie (ABBV) Phase 3 MURANO Study of VENCLEXTA Met Primary Endpoint
Sep 18, 2017 11:29AM AbbVie Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLEXTA™/VENCLYXTO™ (Venetoclax) Tablets in Combination with Rituxan® (rituximab) for the Treatment of Patients with Rela
Sep 11, 2017 08:03AM AbbVie (ABBV) Reports Upadacitinib (ABT-494) Meets All Primary & Ranked Secondary Endpoints in Second Phase 3 Study
View More Recent Stories View Older Stories